Christopher I. Wright - 31 May 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
Director
Signature
/s/ Shantale Greenson, attorney-in-fact for Christopher I. Wright
Issuer symbol
ALKS
Transactions as of
31 May 2024
Net transactions value
+$25,411
Form type
4
Filing time
04 Jun 2024, 17:05:16 UTC
Previous filing
10 Jul 2023
Next filing
10 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $398 +14 +2% $28.40 728 17 Nov 2023 Ordinary Shares 14 $28.40 Direct F1, F2
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $10,082 +355 +2% $28.40 18,128 17 Nov 2023 Ordinary Shares 355 $28.40 Direct F1, F3
transaction ALKS Restricted Stock Unit Award Other +129 +2% 6,602 17 Nov 2023 Ordinary Shares 129 Direct F1, F4, F5
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $7,129 +231 +2% $30.86 11,785 17 Nov 2023 Ordinary Shares 231 $30.86 Direct F1, F2
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $7,803 +254 +2% $30.72 12,986 17 Nov 2023 Ordinary Shares 254 $30.72 Direct F1, F6
transaction ALKS Restricted Stock Unit Award Other +119 +2% 6,104 17 Nov 2023 Ordinary Shares 119 Direct F1, F4, F7
transaction ALKS Restricted Stock Unit Award Award $0 +8,013 $0.000000 8,013 31 May 2024 Ordinary Shares 8,013 Direct F4, F8
transaction ALKS Non Qualified Stock Option (Right to Buy) Award $0 +17,492 $0.000000 17,492 31 May 2024 Ordinary Shares 17,492 $23.40 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
F2 These options are fully vested in accordance with their terms.
F3 Shares subject to the stock option award vest in three equal annual installments commencing on 6/8/2023.
F4 Each restricted stock unit represents a contingent right to receive one ordinary share.
F5 Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023.
F6 Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
F7 Shares subject to the restricted stock unit award vest in full on 6/29/2024.
F8 Shares subject to the restricted stock unit award vest in full on 5/31/2025.
F9 Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.

Remarks:

EXHIBIT LIST: Exhibit 24.1 - Power of Attorney